Vulvar Diseases clinical trials at University of California Health

1 research study open to eligible people

Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
at UC Davis

Our lead scientists for Vulvar Diseases research studies include Tianhong Li, MD.

Last updated: July 7, 2025

Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors